GBI Research’s report, “Kidney and Renal Diseases Therapeutics Market to 2017 – Strong Pipeline and Unmet Need Due to Poor Safety Profiles and to Create Opportunities for Growth”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market.

1. Kidney and Renal Diseases Therapeutics Market to 2017 – Strong Pipeline and
Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
GBI Research’s report, “Kidney and Renal Diseases Therapeutics Market to 2017 – Strong
Pipeline and Unmet Need Due to Poor Safety Profiles and to Create Opportunities for
Growth”, provides in-depth analysis of unmet needs, drivers and barriers that impact the
global kidney and renal diseases therapeutics market.
Buy Now: Kidney and Renal Diseases Therapeutics Market
Browse All: Latest Market Research Reports
The report analyzes the markets for kidney and renal diseases therapeutics in the US, the
top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.
Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key
geographies as well as the leading therapeutic segments. Further, the report provides
competitive benchmarking for the leading companies and analyzes the mergers, acquisitions
and licensing agreements that shape the global markets.
Scope
The scope of this report includes -
 Annualized market data for the kidney and renal diseases therapeutics market from 2001
to 2010, forecast forward to 2017
 Analysis of the leading therapeutic segments.
 Analysis of the kidney and renal diseases therapeutics market in the leading geographies
of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
 Market characterization of the kidney and renal diseases therapeutics market including
market size, annual cost of therapy, and treatment usage patterns
 Key drivers and barriers that have a significant impact on the market
 Coverage of pipeline molecules in various phases of drug development
 Competitive benchmarking of leading companies.
 Key M&A activities, licensing agreements, that have taken place between 2008 and 2010
in the global kidney and renal diseases therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
 Align your product portfolio to the markets with high growth potential.
 Develop market-entry and market expansion strategies by identifying the leading
therapeutic segments and geographic markets poised for strong growth.
 Reinforce R&D pipelines by identifying new target mechanisms which can produce first-
in-class molecules with more efficiency and better safety.

2.  Develop key strategic initiatives by understanding the key focus areas of leading
companies.
 Exploit in-licensing and out-licensing opportunities by identifying products that could fill
portfolio gaps.
Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 10
2.1 GBI Research Report Guidance 11
3 Kidney and Renal Diseases Therapeutics Market to 2017: Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for the Global Kidney and Renal Disease Market 13
3.2.1 Revenue 13
3.2.2 Annual Cost of Treatment (ACT) 14
3.3 Treatment Usage Patterns 15
3.3.1 Diseased Population 17
3.3.2 Treatment Seeking Population 18
3.3.3 Diagnosis Population 19
3.3.4 Prescription Population 20
4 Kidney and Renal Diseases Therapeutics Market to 2017: Geographical
Landscape 21
4.1 Revenue Analysis by Geography 21
4.2 The US 23
4.2.1 Revenue 23
4.2.2 Annual Cost of Treatment 24
4.3 Top Five Countries of Europe 25
4.3.1 Revenue 25
4.3.2 Annual Cost of Treatment 26
4.4 Japan 27
4.4.1 Revenue 27
4.4.2 Annual Cost of Treatment 28
5 Kidney and Renal Diseases Therapeutics Market to 2017: Therapeutic Landscape
29
5.1 Chronic Kidney Diseases Market 29
5.1.1 Introduction 29
5.1.2 Revenue 30

3. 5.1.3 Annual Cost of Treatment 32
5.1.4 Treatment Usage Patterns 33
5.1.5 Drivers and Barriers for the Chronic Kidney Diseases Market 39
5.1.6 Drivers for the Chronic Kidney Disease Market 39
5.1.7 Barriers for the Chronic Kidney Disease Market 39
5.2 Renal Anemia Market 40
5.2.1 Introduction 40
5.2.2 Revenue 40
5.2.3 Annual Cost of Treatment 43
5.2.4 Treatment Usage Patterns 44
5.2.5 Drivers and Barriers for the Renal Anemia Market 50
5.2.6 Drivers for the Renal Anemia Market 51
5.2.7 Barriers for the Renal Anemia Market 51
5.3 Diabetic Nephropathy Market 52
5.3.1 Introduction 52
5.3.2 Revenue 52
5.3.3 Annual Cost of Treatment 55
5.3.4 Treatment Usage Patterns 56
5.3.5 Drivers and Barriers for the Diabetic Nephropathy Market 61
5.3.6 Drivers for the Diabetic Nephropathy Market 61
5.3.7 Barriers for the Diabetic Nephropathy Market 61
5.4 Acute Kidney Injury Market 62
5.4.1 Introduction 62
5.4.2 Revenue 63
5.4.3 Annual Cost of Treatment 65
5.4.4 Treatment Usage Patterns 67
5.4.5 Drivers and Barriers for the Acute Kidney Injury Market 73
5.4.6 Drivers for the Acute Kidney Injury Market 73
5.4.7 Barriers for the Acute Kidney Injury Nephropathy Market 73
6 Kidney and Renal Diseases Therapeutics Market to 2017 – Product Pipeline
Analysis 74
6.1 Introduction 74
6.1.1 Research and Development Pipeline – Chronic Kidney Disease (CKD) 75
6.1.2 Research and Development Pipeline – Renal Anemia (RA) 81
6.1.3 Research and Development Pipeline – Diabetic Nephropathy (DN) 83
6.1.4 Research and Development Pipeline – Acute Kidney Injury (AKI) 86
6.2 Profiles of Promising Drugs in the Kidney and Renal Disease Market 89
6.2.1 AMG 223 89
6.2.2 AST-120 90
6.2.3 CellCept 90
6.2.4 Ferinject 91

4. 6.2.5 Genz-644470 92
6.2.6 Hematide 93
6.2.7 HEPLISAV 93
6.2.8 Heptar 94
6.2.9 SBR759 95
6.2.10 Sulodexide 96
6.2.11 YM533 96
6.2.12 Zuragen 97
6.2.13 Olmetec 97
7 Kidney and Renal Diseases Therapeutics Market to 2017 – Competitive
Landscape 99
7.1 Market Share Analysis 99
7.2 Amgen Inc. 100
7.2.1 Company Overview 100
7.2.2 Business Overview 100
7.2.3 SWOT Analysis 101
7.3 Merck & Co., Inc. 102
7.3.1 Company Overview 102
7.3.2 Business Overview 102
7.3.3 SWOT Analysis 103
7.4 Bristol-Myers Squibb Company 104
7.4.1 Company Overview 104
7.4.2 Business Overview 104
7.4.3 SWOT Analysis 105
7.5 Hoffmann-La Roche Inc. 106
7.5.1 Company Overview 106
7.5.2 Business Overview 106
7.5.3 SWOT Analysis 107
7.6 Shire Inc. 108
7.6.1 Company Overview 108
7.6.2 Business Overview 108
7.6.3 SWOT Analysis 109
8 Kidney and Renal Diseases Therapeutics Market to 2017 – M&A Landscape 110
8.1 M&A Deals 110
8.1.1 Deal Summary 111
8.1.2 Deals by Geography 113
8.2 Licensing Deals 114
8.2.1 Summary of Licensing Deals (2009-2010) 115
8.3 Co-development Deals 117
8.3.1 Summary of Co-development Deals (2009-2010) 118

5. 9 Kidney and Renal Diseases Therapeutics Market to 2017 – Appendix 120
9.1 Market Definitions 120
9.2 Abbreviations 120
9.3 Research Methodology 121
9.3.1 Coverage 121
9.3.2 Secondary Research 122
9.3.3 Primary Research 122
9.3.4 Expert Panel Validation 124
9.4 Contact Us 124
9.5 Disclaimer 124
9.6 Sources 124
1.1 List of Tables
Table 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn),
2002-2010
Table 2: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn),
2010-2017
Table 3: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment
($), 2002-2010
Table 4: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment
($), 2010-2017
Table 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern
(millions), 2002-2010
Table 6: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern
(millions), 2010-2017
Table 7: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by
Geography ($bn), 2002-2010
Table 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by
Geography ($bn), 2010-2017
Table 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn),
2002-2010
Table 10: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts
($bn), 2010-2017
Table 11: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of
Treatment ($), 2002-2010
Table 12: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of
Treatment ($), 2010-2017
Table 13: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe,
Revenue Forecasts ($bn), 2002-2010
Table 14: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe,
Revenue Forecasts ($bn), 2010-2017

6. Table 15: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe,
Annual Cost of Treatment ($), 2002-2010
Table 16: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe,
Annual Cost of Treatment ($), 2010-2017
Table 17: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn),
2002-2010
Table 18: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn),
2010-2017
Table 19: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment
($), 2002-2010
Table 20: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment
($), 2010-2017
Table 21: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Revenue Forecasts ($bn), 2002-2010
Table 22: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Revenue Forecasts ($bn), 2010-2017
Table 23: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease,
Revenue by Geography ($bn), 2002-2010
Table 24: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease,
Revenue by Geography ($bn), 2010-2017
Table 25: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Annual
Cost of Treatment by Geography ($), 2002-2010
Table 26: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Annual
Cost of Treatment by Geography ($), 2010-2017
Table 27: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Treatment Usage Pattern (millions), 2002-2010
Table 28: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Treatment Usage Pattern (millions), 2010-2017
Table 29: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Revenue
Forecasts ($bn), 2002-2010
Table 30: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Revenue
Forecasts ($bn), 2010-2017
Table 31: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Revenue by
Geography ($bn), 2002-2010
Table 32: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Revenue by
Geography ($bn), 2010-2017
Table 33: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Annual Cost of
Treatment by Geography ($), 2002-2010
Table 34: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Annual Cost of
Treatment by Geography ($), 2010-2017
Table 35: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment
Usage Pattern (millions), 2002-2010

7. Table 36: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment
Usage Pattern (millions), 2010-2017
Table 37: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Revenue Forecasts ($bn), 2002-2010
Table 38: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Revenue Forecasts ($bn), 2010-2017
Table 39: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Revenue
by Geography ($bn), 2002-2010
Table 40: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Revenue
by Geography ($bn), 2010-2017
Table 41: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Annual
Cost of Treatment by Geography ($), 2002-2010
Table 42: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Annual
Cost of Treatment by Geography ($), 2010-2017
Table 43: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Treatment Usage Pattern (millions), 2002-2010
Table 44: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Treatment Usage Pattern (millions), 2010-2017
Table 45: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Revenue Forecasts ($bn), 2002-2010
Table 46: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Revenue Forecasts ($bn), 2010-2017
Table 47: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Revenue by
Geography ($bn), 2002-2010
Table 48: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Revenue by
Geography ($bn), 2010-2017
Table 49: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Annual Cost
of Treatment by Geography ($), 2002-2010
Table 50: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Annual Cost
of Treatment by Geography ($), 2010-2017
Table 51: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Treatment Usage Pattern (millions), 2002-2010
Table 52: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Treatment Usage Pattern (millions), 2010-2017
Table 53: Research and Development Pipeline – Chronic Kidney Disease (CKD) – 2011
Table 54: Research and Development Pipeline – Renal Anemia (RA) – 2011
Table 55: Research and Development Pipeline – Diabetic Nephropathy (DN) – 2011
Table 56: Research and Development Pipeline – Acute Kidney Injury (AKI) – 2011
Table 57: Kidney and Renal Diseases Therapeutics Market, Global Major M&A Deals, 2004-
2010
Table 58: Kidney and Renal Diseases Therapeutics Market, Global Licensing Deals, 2004-
2010

8. Table 59: Kidney and Renal Diseases Therapeutics Market, Global Major Co-development
Deals, 2004-2010
1.2 List of Figures
Figure 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn),
2002-2017
Figure 2: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment
($), 2002-2017
Figure 3: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern
(millions), 2002-2017
Figure 4: Kidney and Renal Diseases Therapeutics Market, Global, Diseased Population
(millions), 2002-2017
Figure 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Seeking
Population (millions), 2002-2017
Figure 6: Kidney and Renal Diseases Therapeutics Market, Global, Diagnosed Population
(millions), 2002-2017
Figure 7: Kidney and Renal Diseases Therapeutics Market, Global, Prescription Population
(millions), 2002-2017
Figure 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by
Geography ($bn), 2002-2017
Figure 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts
($bn), 2002-2017
Figure 10: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of
Treatment ($), 2002-2017
Figure 11: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe,
Revenue Forecasts ($bn), 2002-2017
Figure 12: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe,
Annual Cost of Treatment ($), 2002-2017
Figure 13: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts
($bn), 2002-2017
Figure 14: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of
Treatment ($), 2002-2017
Figure 15: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Revenue Forecasts ($bn), 2002-2017
Figure 16: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease,
Revenue by Geography ($bn), 2002-2017
Figure 17: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Annual
Cost of Treatment by Geography ($), 2002-2017
Figure 18: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Treatment Usage Pattern (millions), 2002-2017
Figure 19: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Diseased Population (millions), 2002-2017

9. Figure 20: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Treatment Seeking Population (millions), 2002-2017
Figure 21: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Diagnosed Population (millions), 2002-2017
Figure 22: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Disease, Global
Prescription Population (millions), 2002-2017
Figure 23: Kidney and Renal Diseases Therapeutics Market, Chronic Kidney Diseases, Global
Market Drivers and Barriers, 2010-2017
Figure 24: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Revenue
Forecasts ($bn), 2002-2017
Figure 25: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Revenue by
Geography ($bn), 2002-2017
Figure 26: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Annual Cost of
Treatment by Geography ($), 2002-2017
Figure 27: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment
Usage Pattern (millions), 2002-2017
Figure 28: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Diseased
Population (millions), 2002-2017
Figure 29: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Treatment
Seeking Population (millions), 2002-2017
Figure 30: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Diagnosed
Population (millions), 2002-2017
Figure 31: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global
Prescription Population (millions), 2002-2017
Figure 32: Kidney and Renal Diseases Therapeutics Market, Renal Anemia, Global Market
Drivers and Barriers, 2010-2017
Figure 33: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Revenue Forecasts ($bn), 2002-2017
Figure 34: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Revenue
by Geography ($bn), 2002-2017
Figure 35: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Annual
Cost of Treatment by Geography ($), 2002-2017
Figure 36: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Treatment Usage Pattern (millions), 2002-2017
Figure 37: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Diseased Population (millions), 2002-2017
Figure 38: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Treatment Seeking Population (millions), 2002-2017
Figure 39: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Diagnosed Population (millions), 2002-2017
Figure 40: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Prescription Population (millions), 2002-2017

10. Figure 41: Kidney and Renal Diseases Therapeutics Market, Diabetic Nephropathy, Global
Market Drivers and Barriers, 2010-2017
Figure 42: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Revenue Forecasts ($bn), 2002-2017
Figure 43: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Revenue
by Geography ($bn), 2002-2017
Figure 44: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Annual
Cost of Treatment by Geography ($), 2002-2017
Figure 45: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Treatment Usage Pattern (millions), 2002-2017
Figure 46: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Diseased Population (millions), 2002-2017
Figure 47: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Treatment Seeking Population (millions), 2002-2017
Figure 48: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Diagnosed Population (millions), 2002-2017
Figure 49: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Prescription Population (millions), 2002-2017
Figure 50: Kidney and Renal Diseases Therapeutics Market, Acute Kidney Injury, Global
Market Drivers and Barriers, 2010-2017
Figure 51: Kidney and Renal Diseases Therapeutics Market, Global Product Pipeline by Phase
(%), 2011
Figure 52: Research and Development Pipeline – Chronic Kidney Disease (CKD) – 2011
Figure 53: Research and Development Pipeline – Renal Anemia (RA) – 2011
Figure 54: Research and Development Pipeline – Diabetic Nephropathy (DN) – 2011
Figure 55: Research and Development Pipeline – Acute Kidney Injury (AKI) – 2011
Figure 56: Kidney and Renal Diseases Therapeutics Market, Global, Top Companies Share
(%), 2009
Figure 57: SWOT Analysis of Amgen Inc.
Figure 58: SWOT Analysis of Merck & Co., Inc.
Figure 59: SWOT Analysis of Bristol-Myers Squibb Company
Figure 60: SWOT Analysis of Roche
Figure 61: SWOT Analysis of Shire
Figure 62: Kidney and Renal Diseases Therapeutics Market, Global, Major M&A Deals by
Geography, 2005-2010
Figure 63: Kidney and Renal Diseases Therapeutics Market, Global, Major Licensing Deals by
Geography, 2005-2010
Figure 64: GBI Research Market Forecasting Model

11. Related Reports:
 Brazilian Market for Dental Imaging Equipment 2011 (Digital Intraoral X-Ray Systems,
Extraoral X-Ray Systems and CBCT Scanners)
 Russian Market for Dental Imaging Equipment 2011 (Digital Intraoral X-Ray Systems,
Extraoral X-Ray Systems and CBCT Scanners)
 Indian Market for Dental Imaging Equipment 2011 (Digital Intraoral X-Ray Systems,
Extraoral X-Ray Systems and CBCT Scanners)
 Chinese Market for Dental Imaging Equipment 2011 (Digital Intraoral X-Ray Systems,
Extraoral X-Ray Systems and CBCT Scanners)
 U.S. Hyaluronic Acid Viscosupplementation Physician Survey 2011
About Us
ReportsnReports is an online library of over 75,000 market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on:
 Twitter: http://twitter.com/marketsreports
 Facebook:http://www.facebook.com/pages/ReportsnReports/191441427571689
 Blog : http://www.reportsnreportsblog.com/
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsnreports.com
Website: http://www.reportsnreports.com